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OKT3 , a murine monoclonal antibody specific to the
human  CD3 complex,  induces  immunosuppression
by  depletion  of  T  cells.  Administration  of  OKT3
results  in  significant  release  of  proinflammatory
cytokines,  such  as  TNFa and  IL1b .  Liver  recipients
who experience rejection within 3 weeks after trans-
plantation  with  OKT3  prophylaxis  recover  their  T
cells by postoperative day 10 despite complete initial
clearance.
We sought to analyze the role of proinflammatory
and Th–1 cytokines in T cell recovery and rejection
after liver transplantation with OKT3 prophylaxis. In
plasma samples from 32 patients, we measured TNFa ,
IL1b and IL6 (before transplant and on postoperative
days  1,  2  and  3)  and  IL2,  IFNg ,  sIL2R  and  sICAM
(postoperative  days  5,  7  and  10)  and  examined
possible correlations with T-cell recovery and occur-
rence of rejection within 3 weeks.
TNFa ,  IL1b ,  and  IL6  did not  correlate  with  T-cell
recovery. In patients who rejected, IL2 and IFNg on
postoperative days 5 and 7 correlated with degree of
T-cell recovery by day 10; a significant rise in sIL2R
over time also correlated with T-cell recovery in this
group.
Our results emphasize the role of Th–1 cytokines in
rejection following OKT3 induction and suggest that
markers of T cell activation may predict risk.
Key  words:  Liver  transplantation,  Cytokines,  OKT3,
Rejection
Introduction
OKT3, a murine monoclonal antibody specific to the
human  CD3  complex,  induces  immunosuppression
by attaching to the CD3 portion of T lymphocytes,
leading  to  clearance of  the  entire  antigen  receptor
complex  and  depletion  of T  cells.  OKT3  has  been
considered a  major advance in  the  prevention  and
treatment  of  allograft  rejection.  Although  several
studies have shown OKT3 to be effective for prophy-
laxis  against  rejection  of  liver  allografts,1 acute
rejection has been documented in patients receiving
this treatment.
Cytokines  play  a  crucial  role  in  acute  rejection,
which  is  primarily  a  cell-mediated  process. Several
studies  have  examined  the  relationship  between
various cytokines and rejection in attempts to predict
failure of immunotherapy after OLT. TNFa and IL1b
have been shown to be elevated early after transplant
and  have  been  implicated  in  the  up-regulation  of
adhesion molecules,  such  as  ICAM1  and VCAM,  in
patients experiencing rejection.2 The central role of
IL2  in  T  cell  activation  and  proliferation  is  well
documented, while IFNg has been shown to stimulate
B cells, macrophages and expression of MHC class I
and II molecules.3
Administration  of  OKT3  results  in  significant
release of proinflammatory cytokines, such as TNFa
and  IL1b.  Circulating  levels  of  the  T-cell  derived
cytokines  IFNg and  IL2  also  rise  following  OKT3
injection.4 Both proinflammatory and Th–1 cytokines
disappear from  the circulation within 12–24  hours
after injection.4 It is not clear, however, whether the
extent of this cytokine release influences the occur-
rence of allograft rejection after OLT.
A recent study conducted at our institution demon-
strated a 30.8% rate of rejection within 3 weeks of
liver transplantation in patients who received OKT3-
induced  immunosuppression.5 The  same  study
revealed that rejection in these patients is preceded
by  recovery of T cells by  POD10 despite complete
initial  clearance  and  therapeutic  blood  levels  of
OKT3. In the present study, we sought to clarify the
roles of pro-inflammatory cytokines and Th–1 mark-
ers  in  T  cell  recovery  after  OKT3  induction  and
determine their value as predictors of early rejection.
For  the  present  investigation,  samples  from  the
patients in our original study were assayed for TNFa,
IL6  and  IL1b preoperatively  and  on  the  first  3
postoperative  days.  Samples  from  POD5  and  later
were analyzed for IFNg and IL2 as well as sIL2R and
sICAM.
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Study population
We studied 32  patients who underwent orthotopic
liver transplantation for hepatitis C at The Mount Sinai
Medical  Center between  May  1994  and  September
1996  and  who  received  OKT3  (Ortho  Biotech,
Raritan,  NJ)  to  induce  immunosuppression  with
azathioprine and steroids.
Immunosuppression
Patients received OKT3,  5mg  IV  daily,  for  8  to 12
days, with the first dose given intraoperatively after
revascularization of  the graft. Patients also received
methylprednisolone, 500mg IV, prior to each of the
first two postoperative doses. Each subsequent dose
of  OKT3  was  preceded by  a  tapered steroid dose.
Before each of the first three doses of OKT3, patients
were  also  premedicated  with  diphenhydramine,
50mg IV, and acetaminophen. All patients were also
given 1.5mg/kg of azathioprine during OKT3 therapy.
Treatment with cyclosporine or tacrolimus was initi-
ated  on  POD4,  and  OKT3  was  continued  until
therapeutic  blood  levels  of  these agents  were  ach-
ieved. All patients received at least 8 days of OKT3
therapy.
Evaluation of early graft function
Prothrombin time (PT), AST, and ALT were recorded
daily  until  discharge  or  death.  Poor  early  graft
function (PEGF) was defined as PT on POD 2 >18 sec
and  peak AST  or ALT  >2500  during  the  first  three
postoperative days.6
CD3 cell counts and OKT3 levels
Absolute CD3 counts (cells/ml) were measured from
blood samples taken preoperatively and at three time
points  during  OKT3  induction:  early  (POD2–4),
middle  (POD5–7)  and  late  (POD8–10).  CD3  cells
were  labeled  using  an  anti-CD3 (IgG1)  FITC-conju-
gated  monoclonal  antibody  (Coulter  Immunology,
Hialeah, FL) and counted using flow cytometry. The
percentage recovery of  baseline  was  calculated for
each patient at each time point.
Rejection
Rejections that occurred within the first 21 days after
transplant  were  considered  early  rejections;  the
remaining  patients  were  placed  in  the  no-rejection
group.  Rejection  was  diagnosed  on  the  basis  of
elevated LFTs and biopsy showing bile duct damage,
mixed  portal  inflammatory  infiltration,  eosinophils
and  endophlebitis.  Rejection episodes were treated
with methylprednisolone, 1gm IV, for 2 days. None of
the  patients  developed  steroid-resistant  rejection
requiring further antilymphocyte therapy.
Sample collection
Blood was drawn preoperatively and on POD1, 2, 3, 5,
7 and 10. Samples were immediately centrifuged at
3600rpm for 10 minutes, after which the plasma or
serum  was  separated  and  stored  at  –80  C  until
assayed.
Cytokine, ICAM1 and sIL2R levels
Preoperative samples and those from POD1, 2 and 3
were assayed for TNFa, IL1b and IL6. Samples from
POD5, 7 and 10 were assayed for IFNg, IL2, sIL2R, and
sICAM1.  Commercial  ELISA  kits  were  used  and
samples were run in duplicate in all cases. Kits for
TNFa, IL6, IL1b, IL2, IFNg, and sIL2R were obtained
from Immunotech (Marseille, France) and the ELISA
assay for sICAM1 was purchased from R&D Systems
(Minneapolis, MN). Optical densities were read using
Bio-Kinetic  reader  model  EL312e  (Bio-Tek  Instru-
ments, Winsooski, VT).
Data Analysis
Student’s t-test assuming unequal variance was used
to compare results between the early rejection and
no-rejection groups. ANOVA with repeated measures
was  used  to  compare  data  from  different  post-
operative days within both the early rejection or no
rejection  groups.  Chi-square  test  was  applied  to
compare  the  incidence  of  PEGF  between  study
groups. A p value of less than 0.05 was considered
significant  for  both  tests.  Correlation  was  used  to
compare data within each group, and an R 2 value of
greater than 0.55 was considered significant.
Results
Six patients were excluded (one for death on POD11
from sepsis, one for retransplantation on POD14 for
hepatic artery thrombosis, three for early discontinua-
tion  of  OKT3  due  to  adverse  effects,  and  one  for
discharge  home  on  POD8  prior  to  the  last  blood
sample being drawn). Final analysis was performed on
samples  from  26  patients.  Rejection  episodes (one
mild, six moderate and one severe) were diagnosed in
eight  patients;  the  results  from  the  remaining  18
patients  were  analyzed  in  the  no-rejection  group.
Although  patients  with  no  rejection  demonstrated
somewhat more profound IRI, the differences in the
extent of IRI or in the incidence of PEGF did not reach
statistical significance (Table 1).
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(range: POD10–20). T-cell counts are listed in Table
2.
Mean TNFa and  IL6  levels  were  highly  variable
among patients in both groups, and no clear trends
developed  from  the  preoperative  sample  point  to
POD3. We found higher mean TNFa and IL6 levels in
the no-rejection patients on all 4 days measured, but
this difference reached significance only for IL6 on
POD3 (Table 3). TNFa and IL6 did not correlate with
efficacy of OKT3 therapy, as measured by clearance of
T cells, in either group or with eventual recovery of T
cells  in  the  rejection  group.  TNFa levels  strongly
correlated  with  IL6  levels  on  POD2  and  POD3  in
patients  with  rejection  (R 2=  0.8739  and  0.9794
respectively) but not in the no-rejection group. IL1b
was detectable in only two of the samples analyzed.
The rejection group experienced a rise in mean IL2
levels from POD5 to POD10, while levels fell in the
no-rejection  group  (Table  4).  These  changes  from
POD5 to POD10 were not statistically significant, and
neither were the differences between the two groups.
IL2 levels on POD5 and POD7 were found to correlate
with eventual recovery of T cells on POD10 in the
rejection group only (R 2=0.7923 and 0.7079 respec-
tively) (Fig. 1).
Mean  IFNg levels  were  higher  in  the  rejection
group compared with the no-rejection group on all 3
days measured, but these differences never reached
significance. There was also no clear trend over time
for mean IFNg levels in either group. IFNg levels on
POD5 correlated well with degree of T-cell recovery
by  POD10  in  the  rejection  group  (R 2 =  0.6387)
(Table 4).
Mean  levels  of  sIL2R  were  higher  in  the  no-
rejection group on all 3 days measured. There was a
statistically significant difference between the groups
on  POD5  and  POD7  (Table  4). The  two  groups  of
patients displayed different patterns over time; mean
levels rose with marginal significance from POD5 to
POD10  in  the  rejection  group  (p =  0.05)  but  fell
significantly  in  the  no-rejection  group  (p =  0.03).
Changes in sIL2R from POD5 to POD7 correlated very
strongly with eventual recovery of T cells on POD10
(Fig. 2). The difference in sIL2R from POD5 to POD7
also correlated with IL2 and IFNg levels on POD5 (R 2
= 0.6509 and 0.7857). These correlations were true
only of the rejection group.
Average levels of sICAM1 were significantly higher
in the no-rejection group on POD5 (Table 4). Like IL2,
the  values  for  sICAM1  fell  after  POD5  in  the  no-
rejection group and rose in the rejection group, but
these changes were not statistically significant. There
was a strong correlation between sICAM1 and sIL2R
levels on POD5 in both the rejection and no-rejection
groups (R2 = 0.7433 and 0.5914, respectively).
Discussion
Induction  with  OKT3  after  OLT  has  been  used  by
many centers in attempts to decrease early cyclospor-
ine-related renal dysfunction as well as the incidence
Cytokine in rejection following OKT3 treatment
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peak AST 560±219 1038±1358 NS
peak ALT 536±259 739±838 NS
PT on POD2 13.9±0.88 15.8±2.9 NS
PEGF 0/8 2/18 NS






Absolute CD3 count (cells/ml)
Baseline 266.1±196.3 529.7±378.2 NS
POD2–4 7.9±14.2 4.4±4.7 NS
POD5–7 20.1±25.3 19.9±50.5 NS
POD8–10 213.3±184.9 22.7±32.4 <0.001
% recovery of baseline
POD2–4 3.3±3.2 1.4±2.6 NS
POD5–7 7.6±12.9 3.6±8.4 NS
POD8–10 107.9±85.7 6.7±7.9 <0.001of acute rejection. Studies have shown, however, that
acute rejection with OKT3 prophylaxis still occurs in
26%  to  33%  of  patients.1 The  mechanisms  that
contribute  to  rejection  in  the  presence  of  OKT3
prophylaxis are not well understood, and no reliable
methods for prediction of rejection in  this  circum-
stance are available.
Our current results demonstrate that proinflamma-
tory  cytokine  profiles  evaluated preoperatively  and
during the first 3 postoperative days did not correlate
with the efficacy of OKT3 treatment as indicated by
T-cell clearance. Additionally, elevated TNFa, IL1b and
IL6 levels in the first 3 days were not predictive of
early rejection. Interestingly, levels of these cytokines
were higher in the no-rejection group on all the days
measured.  It  is  difficult  to  assess  the  biological
significance of this finding, as there was such wide
variation in the observed values. On the other hand,
the  strong  correlation  between TNFa and  IL6  on
POD2  and  3,  observed  in  rejecting  patients  only,
suggests  the  presence  of  an  acute  inflammatory
response  in  this  group.  Other  investigators  have
shown early elevations in serum levels of TNFa, IL1b
and  IL6  in  patients  experiencing  acute  rejection
episodes.7,8 Our data, which show higher mean levels
of TNFa and IL6 in patients without early rejection,
seems to contradict these findings. Previous studies,
however, did not use OKT3 for induction therapy. The
type  of  immunosuppression,  among  other  factors,
may therefore have an effect on early proinflamma-
tory cytokine levels.
The  extent  of  ischemia/reperfusion  injury  (IRI),
which is considered to be the major determinant of
early postoperative graft function,6,9,10 may also affect
S. Roayaie et al.
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Pre-op 16.9±22.9 37.1±34.1 0.054
POD1 27.6±22.1 53.5±28.3 0.079
POD2 16.1±11.3 131.9±220.9 0.104
POD3 27.1±32.5 47.9±51.1 0.123
IL6 (pg/ml)
Pre-op 15.1±16.9 91.2±221.8 0.089
POD1 67.4±47.5 345.1±359.8 0.074
POD2 4.5±2.5 135.4±199.2 0.063
POD3 14.3±18.3 147.9±217.5 0.011
IL1b (pg/ml)
Pre-op – 3.83±12.1 NS
POD1 – – NS
POD2 – – NS
POD3 – – NS







POD5 28.88±23.82 53.78±62.41 0.085
POD7 27.75±35.72 28.81±30.76 0.473
POD10 62.10±55.23 23.78±19.81 0.071
IFNg (IU/ml)
POD5 1.42±1.62 0.66±0.70 0.134
POD7 1.05±1.31 0.64±0.97 0.221
POD10 1.45±2.59 0.53±0.73 0.201
sIL2R(pM)
POD5 135.63±69.87 223.33±75.62 0.01
POD7 143.13±58.74 207.5±73.34 0.021
POD10 175.29±53.82 205.17±73.45 0.154
sICAM1(ng/ml)
POD5 612.75±165.47 806.1±309.57 0.03
POD7 649.50±197.82 664.5±267.81 0.49
POD10 695.14±180.63 674.94±281.76 0.423early  postoperative  cytokine  levels.  In  the  present
study, however, early graft function was comparable
among  the  patients in  the  study  groups  suggesting
that the changes in cytokine profiles are more likely
related to the onset of rejection.
OKT3 induction appears to have a similar effect on
both sIL2R and sICAM levels. Mean values for sIL2r
were significantly higher on POD5 and POD7 in the
no-rejection  group,  and  a  similar  difference  was
demonstrated for sICAM on POD5. Significant varia-
tions  in  sIL2R  and  sICAM levels  have been  shown
depending on the type of immunosuppression, with
the highest levels among patients receiving antilym-
phocytic  therapy  such  as  OKT3.8,11 This  is  not
surprising if one considers that both IL2 receptor and
ICAM are membrane-bound protein complexes found
on lymphocytes. The correlation between sIL2R levels
and  sICAM1  levels  on  POD5  in  both  the  early
rejection and no-rejection groups supports a similar
mechanism behind their release.
Mean levels of IL2 and IFNg did not differ between
the two patient groups at any time point. Additionally,
changes in levels of these cytokines measured over
time  were  not  predictive  of  rejection. The  strong
correlations  between  levels  of  IL2  on  POD5  and
POD7, and IFNg on POD5, with the degree of T-cell
recovery  by  POD10,  were  specific  to  the  early
rejection group. These findings suggest that rejection
occurring during OKT3 induction is mediated by Th1
cytokines.  Further  support  for  this  mechanism  is
given by the significant rise in sIL2R levels from POD5
to POD10 in the same group and by the correlation
between the increase in sIL2R levels from POD5 to
POD7 and T-cell recovery.
Several pathways have been proposed as possible
mechanisms  of  acute  rejection  occurring  during
OKT3 induction, including the development of anti-
OKT3 antibodies and low OKT3 levels. Sutherland et
al. demonstrated a clonal expansion of OKT3-resist-
ant, allospecific T cells within the graft of a patient
experiencing  rejection  during  OKT3  induction.3
These  cells  maintained  IL2  production  in  vitro
despite binding of OKT3. This sustained IL2 produc-
tion may be important for the escape phenomenon.
While  systemic  IL2  levels  in  our  study  were  not
different  between the  two  patient groups,  they  do
not accurately reflect intragraft cytokine production.
Although we did not measure in  vitro IL2 produc-
tion  by T  cells  isolated from  our  patients,  the  fact
that a correlation between IL2 levels and subsequent
T  cell  recovery  existed  only  among  patients  with
rejection supports the central role of IL2 in rejection
episodes occurring after OKT3 induction. Our data
suggests  that  even  though  there  is  equivalent  pro-
duction of IL2 and IFNg in both groups, only the T
cells of the patients who will eventually experience
rejection  respond  to  these  cytokines  by  T  cell
proliferation.  Thus,  there  may  be  a  difference  in
sensitivity to IL2 among the lymphocytes of  reject-
ing and non-rejecting patients. Differential sensitivity
of T  cells  to IL2  has  been  demonstrated in  several
studies  and  can  serve  as  another  possible  mecha-
nism for OKT3 resistance.12
The relatively  higher sIL2R  and sICAM1 levels  in
the no rejection group can be explained by the fact
that for any given population of T cells, there will be
a  heterogeneous  response  to  OKT3.3 sICAM1  has
been  shown  to  partially  block  adhesion  of  leuko-
cytes  and  thereby  modify  the  immune  response.13
Rubin et al. have demonstrated that sIL2R efficiently
binds IL2 without producing an immunostimulatory
effect.14
Cytokine in rejection following OKT3 treatment
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FIG. 1. Correlation between IL2 levels on POD5 (A) and POD7
(B) and T-cell recovery on POD10 in rejecting patients.
FIG.  2.  Correlation  between  change  in  sIL2R  levels  from
POD5  to  POD7  and T-cell recovery on POD10 in rejecting
patients.In  summary,  our  study  failed  to  establish  any
correlation between increased levels of TNFa, IL6 and
IL1b and early rejection after OKT3 induction. Our
previous study showed that early rejection after OKT3
induction is preceded by a recovery of T-cell count to
baseline by post-transplant day 10. This T-cell recovery
appears to be a Th–1 driven process, with signs of
T-cell activation around POD5. Monitoring of periph-
eral T-cell  numbers  and  sIL2R  levels  may  help  to
identify patients who are likely to reject despite OKT3
prophylaxis.
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